Таргетная терапия системной красной волчанки: настоящее и будущее
DOI: https://doi.org/10.29296/25877305-2021-11-03
Номер журнала:
11
Год издания:
2021
Системная красная волчанка (СКВ) – аутоиммунное системное заболевание, патогенез которого основан
на дефектах иммунорегуляции, приводящих к неконтролируемой гиперпродукции аутоантител к компонентам
собственных тканей и развитию хронического воспаления, поражающего многие органы и системы. Пристальный
интерес к СКВ в последние десятилетия позволил усовершенствовать методы ее диагностики, однако ведение
пациентов по-прежнему остается сложной задачей. Разработке методов лечения препятствуют неизвестная
этиология заболевания, большая вариабельность клинических проявлений, возможность как длительных спонтанных
ремиссий, так и злокачественного, быстро прогрессирующего, иногда молниеносного течения. Для терапии СКВ в
настоящее время используется практически весь арсенал противовоспалительных и цитотоксических препаратов,
существующих в медицине, применение которых значительно улучшает прогноз жизни пациентов. Современные методы
лечения направлены на подавление аутоиммунного воспаления, предотвращение рецидивов и уменьшение клинических
симптомов и необратимого повреждения органов. В обзоре освещаются иммунные механизмы, преобладающие в новых
целевых методах лечения СКВ.
Ключевые слова:
терапия
системная красная волчанка
клинические исследования
моноклональные антитела
экулизумаб
ритуксимаб
белимумаб
обинтузумаб
табалумаб
атаксицепт
бортезомиб
анифролумаб
сифалимумаб
ронтализумаб
Для цитирования
Н.А. Куницкая Таргетная терапия системной красной волчанки: настоящее и будущее
. Врач, 2021; (11): 18-23 https://doi.org/10.29296/25877305-2021-11-03Список литературы:
- Козлов В.А., Савченко А.А., Кудрявцев И.В. и др. Клиническая иммунология. Красноярск: Поликор, 2020; 386 с. [Kozlov V.A., Savchenko A.A., Kudryavtsev I.V. et al. Klinicheskaya immunologiya. Krasnoyarsk: Polikor, 2020; 386 s. (in Russ.)]. DOI: 10.17513/np.438
- Alexander T., Cheng Q., Klotsche J. et al. Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur J Immunol. 2018; 48: 1573–9. DOI: 10.1002/eji.201847492
- Alshaiki F., Obaid E., Almuallim A. et al. Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol. 2018; 5: 118–26. DOI: 10.5152/eurjrheum.2018.17096
- Aranow C., Dall’Era M., Byron M. et al. FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis. Ann Rheum Dis. 2018; 77: 690.
- Banchereau R., Hong S., Cantarel B. et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell. 2016; 165 (3): 551–65. DOI: 10.1016/j.cell.2016.03.008
- Buyon J.P., Cohen P., Merrill J.T. et al. A highlight from the LUPUS 2014 meeting: eight great ideas. Lupus Sci Med. 2015; 2 (1): e000087. DOI: 10.1136/lupus-2015-000087
- Collins C.E., Dall’Era M., Kan H. et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016; 3 (1): e000118. DOI: 10.1136/lupus-2015-000118
- Clowse M.E., Wallace D.J., Furie R.A. et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 2017; 69: 362–75. DOI: 10.1002/art.39856
- D’Cruz D., Maksimowicz-McKinnon K., Oates J. et al. Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the EMBRACE study. Lupus Sci Med. 2019; 6: A149–A150. DOI: 10.1136/lupus-2019-lsm.200
- Doria A., Stohl W., Schwarting A. et al. Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, cypocomplementemic patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018; 70 (8): 1256–64. DOI: 10.1002/art.40511
- Dorner T., Shock A., Goldenberg D.M. et al. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmun Rev. 2015; 14: 1079–86. DOI: 10.1016/j.autrev.2015.07.013
- Ehrenstein M.R., Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016; 12 (6): 367–72. DOI: 10.1038/nrrheum.2016.18
- Everly M.J., Everly J.J., Susskind B. et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008; 86 (12): 1754–61. DOI: 10.1097/TP.0b013e318190af83
- Fanouriakis A., Kostopoulou M., Alunno A. et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019; 78 (6): 736–45. DOI: 10.1136/annrheumdis-2019-215089
- Fanouriakis A., Kostopoulou M., Cheema K. et al. 2019 Update of the joint European league against rheumatism and european renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020; 79 (6): 713–23. DOI: 10.1136/annrheumdis-2020-216924
- Furie R., Aroca G., Alvarez A. et al. A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis. Arthritis Rheumatol. 2019; 71 (10): 9–39.
- Furie R.A., Leon G., Thomas M. et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015; 74 (9): 1667–75. DOI: 10.1136/annrheumdis-2013-205144
- Furie R., Merrill J., Werth V. et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus. Arthritis Rheumatol. 2015; 67: 3223. DOI: 10.1002/art.39962
- Furie R.A., Morand E.F., Bruce I.N. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019; 208–19. DOI: 10.1016/S2665-9913(19)30076-1
- GlaxoSmithKline. GSK Announces Positive Headline Results in Phase 3 Study of Benlysta in Patients with Lupus Nephritis, 2019. Available online at: https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-in-phase-3-study-of-benlysta-in-patients-with-lupus-nephritis
- Gomez Mendez L.M., Cascino M.D., Garg J. et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018; 13 (10): 1502–9. DOI: 10.2215/CJN.01070118
- Greenbaum L.A., Fila M., Ardissino G. et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016; 89 (3): 701–11. DOI: 10.1016/j.kint.2015.11.026
- Hennessey A., Lukawska J., Cambridge G. et al. Advers infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis. BMC Rheumatol. 2019; 3: 32. DOI: 10.1186/s41927-019-0082-7
- Houssiau F.A., Doria A. Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty? Ann Rheum Dis. 2016; 75 (2): 321–2. DOI: 10.1136/annrheumdis-2015-208312
- Iaccarino L., Bettio S., Reggia R. et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. 2017; 69 (1): 115–23. DOI: 10.1002/acr.22971
- Isenberg D.A., Petri M., Kalunian K. et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75 (2): 323–31. DOI: 10.1136/annrheumdis-2015-207653
- Ishii T., Tanaka Y., Kawakami A. et al. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol. 2018; 28 (6): 986–92. DOI: 10.1080/14397595.2018.1432331
- Jones A., Muller P., Dore C.J. et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019; 9 (12): e032569. DOI: 10.1136/bmjopen-2019-032569
- Kalunian K.C., Merrill J.T., Maciuca R. et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016; 75 (1): 196–202. DOI: 10.1136/annrheumdis-2014-206090
- Kalunian K.C., Merrill J.T., Maciuca R. et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016; 75 (1): 196–202. DOI: 10.1136/annrheumdis-2014-206090
- Kansal R., Richardson N., Neeli I. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019; 11 (482): eaav1648. DOI: 10.1126/scitranslmed.aav1648
- Khamashta M., Merrill J.T., Werth V.P. et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75 (11): 1909–16. DOI: 10.1136/annrheumdis-2015-208562
- Kraaij T., Kamerling S.W.A., de Rooij E.N.M. et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018; 91: 45–54. DOI: 10.1016/j.jaut.2018.03.003
- Kavanagh D., Smith-Jackson K. Eculizumab in children with hemolytic uremic syndrome. Kidney Int. 2016; 89 (3): 537–8. DOI: 10.1016/j.kint.2015.12.039
- Licht C., Greenbaum L.A., Muus P. et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015; 87 (5): 1061–73. DOI: 10.1038/ki.2014.423
- Masoud S., McAdoo S.P., Bedi R. et al. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology. 2018; 57 (7): 1156–61. DOI: 10.1093/rheumatology/key042
- Merrill J.T., Shanahan W.R., Scheinberg M. et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018; 77 (6): 883–9. DOI: 10.1136/annrheumdis-2018-213032
- Merrill J.T., van Vollenhoven R.F., Buyon J.P. et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75 (2): 332–40. DOI: 10.1136/annrheumdis-2015-207654
- Morand E.F., Furie R., Tanaka Y. et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020; 382 (3): 211–21. DOI: 10.1056/NEJMoa1912196
- Murphy G., Isenberg D.A. New therapies for systemic lupus erythematosus – past imperfect, future tense. Nat Rev Rheumatol. 2019; 15 (7): 403–12. DOI: 10.1038/s41584-019-0235-5
- Parodis I., Soder F., Faustini F. et al. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL. Lupus. 2018; 27 (9): 1470–8. DOI: 10.1177/0961203318777116
- Parodis I., Sjowall C., Jonsen A. et al. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev. 2017; 16 (4): 343–51. DOI: 10.1016/j.autrev.2017.02.005
- Parodis I., Gomez A., Frodlund M. et al. Smoking reduces the efficacy of belimumab in mucocutaneous lupus. Expert Opin Biol Ther. 2018; 18 (8): 911–20. DOI: 10.1080/14712598.2018.1494719
- Parodis I., Johansson P., Gomez A. et al. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Rheumatology. 2019; 58 (12): 2170–76. DOI: 10.1093/rheumatology/kez191
- Parodis I., Gomez A., Emamikia S. et al. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. Ann Rheum Dis. 2019; 78 (7): 1006–7. DOI: 10.1136/annrheumdis-2018-214880
- Parodis I., Åkerström E., Sjöwall C. et al. Autoantibody and cytokine profiles during treatment with belimumab in patients with systemic lupus erythematosus. Int J Mol Sci. 2020; 21 (10): 3463. DOI: 10.3390/ijms21103463
- Ramskold D., Parodis .I, Lakshmikanth T. et al. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine. 2019; 40: 517–27. DOI: 10.1016/j.ebiom.2018.12.035
- Reddy V., Dahal L.N., Cragg M.S. et al. Optimising Bcell depletion in autoimmune disease: is obinutuzumab the answer? Drug Discov Today. 2016; 21 (8): 1330–8. DOI: 10.1016/j.drudis.2016.06.009
- Scheinberg M.A., Hislop C.M., Martin R.S. Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser. Expert Opin Biol Ther. 2016; 16 (5): 723–33. DOI: 10.1517/14712598.2016.1169270
- Schweighoffer E., Tybulewicz V.L. Signalling for B cell survival. Curr Opin Cell Biol. 2018; 51: 8–14. DOI: 10.1016/j.ceb.2017.10.002
- Stohl W., Schwarting A., Okada M. et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017; 69 (5): 1016–27. DOI: 10.1002/art.40049
- Sohrabian A., Parodis I., Carlstromer-Berthen N. et al. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Res Ther. 2019; 21 (1): 259. DOI: 10.1186/s13075-019-2056-y
- Teng Y.K.O., Bruce I.N., Diamond B. et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019; 9 (3): e025687. DOI: 10.1136/bmjopen-2018-025687
- Touma Z., Sayani A., Pineau C.A. et al. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada study. Rheumatol Int. 2017; 37 (6): 865–73. DOI: 10.1007/s00296-017-3682-9
- von Kempis J., Duetsch S., Reuschling N. et al. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland. Swiss Med Wkly. 2019; 149: w20022. DOI: 10.4414/smw.2019.20022